Melanotan II while on DNP?

[100%NATURAL-theGH]

Alright I'm running 500mg/day DNP and I wanted to put on some color so when I quit the DNP I can fully appreciate the drop in body fat. Are there any concerns with using the Melanotan II at the same time as DNP?

[fred9]

dunno if there is an interaction between mt2 and dnp, but mt2 increases ur metabolism because mt2 stimulates the making of ucp3 in fat and muscle. MT2 also takes away ur hunger and makes u sleapy...
all those things are quite good while ur on dnp...

[100%NATURAL-theGH]

dunno if there is an interaction between mt2 and dnp, but mt2 increases ur metabolism because mt2 stimulates the making of ucp3 in fat and muscle. MT2 also takes away ur hunger and makes u sleapy...
all those things are quite good while ur on dnp...

I must say I didn't do all my research but I took the shot about 45 minutes ago of just .5 mg of MT II and I got hot and flush pretty quick then it went away.. I hope that is the end of it but someone has to roll the dice now and then... Thanks bro!

[100%NATURAL-theGH]

UM NEW UPDATE: I'm BRIGHT ASS RED!!! What is that???

[cfiler]

The compounds should not react with eachother. There have been alot of members who have run both while on a cycle, with no problem.

Don't know why you are red though? I get that way when I use tanning lotions with tingle in them...

[Jacky_Zebsten]

dunno if there is an interaction between mt2 and dnp, but mt2 increases ur metabolism because mt2 stimulates the making of ucp3 in fat and muscle. MT2 also takes away ur hunger and makes u sleapy...
all those things are quite good while ur on dnp...

I didnt know mt2 increased your metabolism

[fred9]

I didnt know mt2 increased your metabolism

yeah was also new for me, read it a few days ago:

Role of the melanocortin-4 receptor in metabolic rate and food intake in mice.Chen AS, Metzger JM, Trumbauer ME, Guan XM, Yu H, Frazier EG, Marsh DJ, Forrest MJ, Gopal-Truter S, Fisher J, Camacho RE, Strack AM, Mellin TN, MacIntyre DE, Chen HY, Van der Ploeg LH.
Department of Metabolic Disorders, Merck Research Laboratories, NJ, USA.

We evaluated the role of the melanocortin-4 receptor (MC-4R) in the control of metabolic rate and food intake in mice. Intraperitoneal administration of the non-selective MC-R agonist melanotan II (MT-II; a cyclic heptapeptide) increases metabolic rate in wildtype mice, while MC-4R knockout mice are insensitive to the effects of MT-II on metabolic rate. MC-4R knockout mice are also insensitive to the effects of MT-II on reducing food intake. We conclude that MC-4R can mediate control of both metabolic rate and food intake in mice. We infer that a role for MC-3R in mediating the acute effects of MT-II on basal metabolic rate and food intake in wildtype mice seems limited.

PMID: 10951699 [PubMed - indexed for MEDLINE]


The leptin-like effects of 3-d peripheral administration of a melanocortin agonist are more marked in genetically obese Zucker (fa/fa) than in lean rats.Cettour-Rose P, Rohner-Jeanrenaud F.
Department of Medicine, Division of Endocrinology and Diabetology, University of Geneva, Faculty of Medicine, 1211 Geneva 14, Switzerland.

The effects of a 3-d peripheral administration of an alpha-MSH agonist, MTII, on body weight and the expression of uncoupling proteins (UCPs) and carnitine palmitoyltransferase-1 were determined in lean and genetically obese fa/fa rats by comparing MTII-treated animals with two different control groups, one being ad libitum fed, the other pair-fed to the amount of food consumed by MTII-treated rats. MTII treatment of lean and obese rats lowered food intake and body weight, the effects being more marked in obese than in lean rats. In both groups, MTII administration suppressed the increased plasma FFA levels brought about by food restriction. In lean rats, MTII prevented the decrease in brown adipose tissue UCP1, UCP2, and UCP3 expression and muscle UCP3 occurring during food restriction. In obese animals, MTII markedly increased brown adipose tissue (7-fold) and muscle (2.5-fold) UCP3 expression. The decrease in liver carnitine palmitoyltransferase-1 elicited by food restriction in lean and obese rats was prevented by MTII administration. In summary, the effects of MTII resemble those of leptin and are more marked in obese than in lean animals, in keeping with their reported reduced endogenous melanocortin tone. Melanocortin agonists may be useful in the treatment of obesity associated with impaired leptin signaling.